Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR StudyPeter Hillmen,David Allan Cairns,Adrian John Clifton Bloor,David Allsup,Kate Cwynarski,Andrew Pettitt,Shankaranarayana Paneesha, Christopher P. Fox,Toby A. Eyre,Francesco Forconi,Nagah Elmusharaf,Ben Kennedy,John G. Gribben,Nicholas Pemberton,Oonagh Sheehy,Gavin Preston,Anna Schuh,Dena Howard,Anna Hockaday,Sharon Jackson, Natasha Greatorex, Sean Girvan, Sue Bell, Julia Brown, Nichola Webster, Surita Dalal, Ruth M. de Tute, Andrew Rawstron, Piers E. M. Patten, Talha MunirBLOOD（2023）引用 0|浏览4暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
